Why the study?
Dose-adjusted cangrelor based on platelet function testing has been suggested to be advantageous during neuroendovascular procedures, but its efficacy and safety required assessment.
Does low dose intravenous cangrelor prevent stent occlusion or persistent intraluminal thrombus in patients undergoing neuroendovascular procedures?
Population
101 consecutive patients undergoing neuroendovascular procedures for RIA, UIA, or AIS
Comparison
Low dose intravenous cangrelor
Design
Retrospective study
Follow-up
24 hours
Key result
Low dose intravenous cangrelor during neuroendovascular procedures was associated with a 4.9% rate of stent occlusion and a 2% rate of major hemorrhage at 24 hours.
Authors
Loading...
Low rates of occlusion and hemorrhage with low-dose cangrelor support further evaluation; leaves open efficacy confirmation in randomized neuroendovascular trials.
Cohort (n=101)
Does low dose intravenous cangrelor prevent stent occlusion or persistent intraluminal thrombus in patients undergoing neuroendovascular procedures?
Low dose intravenous cangrelor appears effective for preventing stent thrombosis during neuroendovascular procedures with a low risk of major hemorrhage.
Cagnazzo et al. (2023) conducted a cohort in Intracranial aneurysms and acute ischemic stroke (n=101). Low dose intravenous cangrelor was evaluated on Rate of stent occlusion or persistent intraluminal thrombus. Low dose intravenous cangrelor during neuroendovascular procedures was associated with a 4.9% rate of stent occlusion and a 2% rate of major hemorrhage at 24 hours.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: